# Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00045422** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00045422
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045422, "Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00045422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*